NASDAQ:GMAB Genmab A/S (GMAB) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free GMAB Stock Alerts $28.56 -0.41 (-1.42%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$28.54▼$29.0450-Day Range$26.43▼$31.6852-Week Range$26.32▼$42.72Volume559,802 shsAverage Volume589,068 shsMarket Capitalization$18.88 billionP/E Ratio29.75Dividend YieldN/APrice Target$48.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Genmab A/S alerts: Email Address Genmab A/S MarketRank™ Stock AnalysisAnalyst RatingHold2.38 Rating ScoreUpside/Downside69.8% Upside$48.50 Price TargetShort InterestHealthy0.37% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.23Based on 9 Articles This WeekInsider TradingN/AProj. Earnings Growth35.85%From $1.06 to $1.44 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.25 out of 5 starsMedical Sector312th out of 910 stocksPharmaceutical Preparations Industry136th out of 426 stocks 3.2 Analyst's Opinion Consensus RatingGenmab A/S has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 8 buy ratings, 2 hold ratings, and 3 sell ratings.Amount of Analyst CoverageGenmab A/S has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.37% of the float of Genmab A/S has been sold short.Short Interest Ratio / Days to CoverGenmab A/S has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Genmab A/S has recently increased by 17.07%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGenmab A/S does not currently pay a dividend.Dividend GrowthGenmab A/S does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GMAB. Previous Next 2.9 News and Social Media Coverage News SentimentGenmab A/S has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Genmab A/S this week, compared to 4 articles on an average week.Search Interest2 people have searched for GMAB on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added Genmab A/S to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genmab A/S insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.54% of the stock of Genmab A/S is held by insiders.Percentage Held by InstitutionsOnly 7.07% of the stock of Genmab A/S is held by institutions. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Genmab A/S are expected to grow by 35.85% in the coming year, from $1.06 to $1.44 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genmab A/S is 29.75, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 142.86.Price to Earnings Ratio vs. SectorThe P/E ratio of Genmab A/S is 29.75, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 226.84.Price to Earnings Growth RatioGenmab A/S has a PEG Ratio of 2.06. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGenmab A/S has a P/B Ratio of 4.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. About Genmab A/S Stock (NASDAQ:GMAB)Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Read More GMAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GMAB Stock News HeadlinesApril 22, 2024 | globenewswire.comTransactions in Connection with Share Buy-back Program GenmabApril 20, 2024 | finance.yahoo.comGenmab A/S (GMAB)April 23, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… April 20, 2024 | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Expected to Post FY2024 Earnings of $0.88 Per ShareApril 16, 2024 | finanznachrichten.deGenmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2024April 16, 2024 | globenewswire.comGenmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024April 15, 2024 | globenewswire.comTransactions in Connection with Share Buy-back Program GenmabApril 14, 2024 | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Given Average Rating of "Hold" by BrokeragesApril 23, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… April 8, 2024 | globenewswire.comTransactions in Connection with Share Buy-back ProgramApril 5, 2024 | benzinga.comGenmab Stock (NASDAQ:GMAB), Quotes and News SummaryApril 3, 2024 | msn.comGenmab Buys Ovarian Cancer Drug Developer for $1.8 BillionApril 3, 2024 | bizjournals.comProfoundBio to be acquired by Danish biotech giant Genmab for $1.8 billionApril 3, 2024 | msn.comM&A News: Genmab (NASDAQ:GMAB) Is Acquiring ProfoundBio for $1.8BApril 3, 2024 | finance.yahoo.comGenmab Takes The Next Step In Its 'Evolution' With A $1.8 Billion TakeoverApril 3, 2024 | investopedia.comGenmab Buys ProfoundBio for $1.8B to Boost Oncology PortfolioApril 3, 2024 | msn.comGenmab to purchase US-based biotech company ProfoundBio for $1.8 billion in all-cash dealApril 3, 2024 | finance.yahoo.comGenmab Strengthens Oncology Portfolio With $1.8 Bln Acquisition of ProfoundBioApril 3, 2024 | reuters.comDenmark's Genmab to acquire ProfoundBio for $1.8 billionApril 3, 2024 | businesswire.comGenmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBioApril 3, 2024 | globenewswire.comGenmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBioApril 2, 2024 | globenewswire.comTransactions in Connection with Share Buy-back ProgramMarch 25, 2024 | globenewswire.comTransactions in Connection with Share Buy-back ProgramMarch 23, 2024 | wsj.comGenmab A/S ADRMarch 18, 2024 | nz.finance.yahoo.comThe 10 best dressed from the 2024 NAACP Image AwardsMarch 18, 2024 | globenewswire.comCompletion of share buy-back programMarch 15, 2024 | ca.finance.yahoo.comGMAB Apr 2024 30.000 putSee More Headlines Receive GMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today4/23/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GMAB CUSIPN/A CIK1434265 Webwww.genmab.com Phone(457) 020-2728FaxN/AEmployees2,204Year Founded1999Price Target and Rating Average Stock Price Target$48.50 High Stock Price Target$50.00 Low Stock Price Target$46.00 Potential Upside/Downside+69.8%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)$0.96 Trailing P/E Ratio29.75 Forward P/E Ratio26.94 P/E Growth2.06Net Income$631.91 million Net Margins26.50% Pretax Margin34.22% Return on Equity18.06% Return on Assets16.13% Debt Debt-to-Equity RatioN/A Current Ratio13.34 Quick Ratio13.32 Sales & Book Value Annual Sales$2.39 billion Price / Sales7.90 Cash Flow$1.23 per share Price / Cash Flow23.15 Book Value$6.95 per share Price / Book4.11Miscellaneous Outstanding Shares661,230,000Free Float651,047,000Market Cap$18.88 billion OptionableOptionable Beta0.98 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Jan G.J. van de Winkel Ph.D. (Age 63)Co-Founder, President & CEO Comp: $2.85MMr. Anthony Pagano (Age 46)Executive VP & CFO Comp: $1.01MMs. Birgitte Stephensen M.Sc. (Age 63)Executive VP & Chief Legal Officer Comp: $627.66kDr. Martine J. van Vugt Ph.D. (Age 53)Executive VP & Chief Strategy Officer Comp: $684.72kMr. Martin Schultz (Age 48)Senior Director of Clinical Operations & Non-Independent Director Comp: $114.12kDr. Tahamtan Ahmadi (Age 51)Executive VP, Chief Medical Officer & Head of Experimental Medicines Comp: $1.1MDr. Mijke Zachariasse Ph.D. (Age 50)Senior Director, Head of Antibody Research Materials & Non-Independent Director Comp: $156.91kMr. Takahiro Hamatani (Age 49)Senior Director of Finance Japan & Non-Independent Director Comp: $114.12kMr. Anthony Mancini (Age 53)Executive VP & COO Comp: $1.08MMr. Andrew CarlsenSenior Director, VP & Head of Investor RelationsMore ExecutivesKey CompetitorsAlnylam PharmaceuticalsNASDAQ:ALNYBioMarin PharmaceuticalNASDAQ:BMRNTeva Pharmaceutical IndustriesNYSE:TEVAViatrisNASDAQ:VTRSBeiGeneNASDAQ:BGNEView All CompetitorsInstitutional OwnershipFifth Third BancorpSold 358 shares on 4/23/2024Ownership: 0.007%Raymond James & AssociatesSold 24,789 shares on 4/22/2024Ownership: 0.025%Legacy Wealth Asset Management LLCBought 1,611 shares on 4/19/2024Ownership: 0.006%Allspring Global Investments Holdings LLCBought 1,453 shares on 4/18/2024Ownership: 0.000%Park Avenue Securities LLCSold 1,126 shares on 4/10/2024Ownership: 0.002%View All Institutional Transactions Should I Buy Genmab A/S Stock? GMAB Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Genmab A/S: Genmab A/S has a strong pipeline of innovative monoclonal antibody-based products, including the latest versions like tisotumab vedotin, which shows promising results in clinical trials for various cancer indications. The company has successful collaborations with major pharmaceutical companies like Novartis and Johnson & Johnson, providing opportunities for revenue growth and product development. Genmab A/S has a solid financial position with steady revenue growth and a healthy balance sheet, making it a stable investment option in the biopharmaceutical industry. The stock price of Genmab A/S has shown consistent growth over the past year, reflecting positive investor sentiment and potential for further appreciation. With a focus on cutting-edge technologies and research, Genmab A/S is well-positioned to capitalize on the growing demand for targeted cancer therapies, offering long-term growth prospects for investors. Cons Investors should be bearish about investing in Genmab A/S for these reasons: Genmab A/S faces intense competition in the biopharmaceutical industry, which may impact market share and pricing strategies for its products. Regulatory challenges and uncertainties in drug approvals could lead to delays in product commercialization, affecting revenue projections and investor confidence. The biopharmaceutical sector is inherently risky due to the high costs of research and development, potential clinical trial failures, and market volatility, posing risks to investor returns. Fluctuations in exchange rates and global economic conditions may impact Genmab A/S's international operations and financial performance, introducing currency and geopolitical risks for investors. Investing in biopharmaceutical companies like Genmab A/S requires a thorough understanding of complex scientific and regulatory processes, which may pose challenges for investors without specialized knowledge in the field. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, April 13, 2024. Please send any questions or comments about these Genmab A/S pros and cons to contact@marketbeat.com. GMAB Stock Analysis - Frequently Asked Questions Should I buy or sell Genmab A/S stock right now? 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last year. There are currently 3 sell ratings, 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMAB, but not buy additional shares or sell existing shares. View GMAB analyst ratings or view top-rated stocks. What is Genmab A/S's stock price target for 2024? 13 equities research analysts have issued 1-year price objectives for Genmab A/S's stock. Their GMAB share price targets range from $46.00 to $50.00. On average, they anticipate the company's stock price to reach $48.50 in the next year. This suggests a possible upside of 69.8% from the stock's current price. View analysts price targets for GMAB or view top-rated stocks among Wall Street analysts. How have GMAB shares performed in 2024? Genmab A/S's stock was trading at $31.84 at the beginning of the year. Since then, GMAB shares have decreased by 10.3% and is now trading at $28.56. View the best growth stocks for 2024 here. Are investors shorting Genmab A/S? Genmab A/S saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 2,400,000 shares, an increase of 17.1% from the March 15th total of 2,050,000 shares. Based on an average daily trading volume, of 626,600 shares, the days-to-cover ratio is presently 3.8 days. Currently, 0.4% of the company's stock are short sold. View Genmab A/S's Short Interest. When is Genmab A/S's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our GMAB earnings forecast. How were Genmab A/S's earnings last quarter? Genmab A/S (NASDAQ:GMAB) posted its earnings results on Wednesday, February, 14th. The company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.34 by $0.02. The business earned $675.29 million during the quarter, compared to analysts' expectations of $678.14 million. Genmab A/S had a net margin of 26.50% and a trailing twelve-month return on equity of 18.06%. What ETFs hold Genmab A/S's stock? ETFs with the largest weight of Genmab A/S (NASDAQ:GMAB) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), Tema Oncology ETF (CANC), iShares Biotechnology ETF (IBB), B.A.D. Etf (BAD), Range Cancer Therapeutics ETF (CNCR) and Loncar China Biopharma ETF (CHNA).Goldman Sachs Future Health Care Equity ETF (GDOC). What guidance has Genmab A/S issued on next quarter's earnings? Genmab A/S issued an update on its FY 2024 earnings guidance on Wednesday, February, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.7 billion-$3.0 billion, compared to the consensus revenue estimate of $2.8 billion. What other stocks do shareholders of Genmab A/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genmab A/S investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), CVS Health (CVS), Home Depot (HD), Intel (INTC), Pfizer (PFE), PayPal (PYPL), Verizon Communications (VZ) and Cisco Systems (CSCO). When did Genmab A/S IPO? Genmab A/S (GMAB) raised $503 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 27,800,000 shares at $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers. Who are Genmab A/S's major shareholders? Genmab A/S's stock is owned by many different institutional and retail investors. Top institutional shareholders include Raymond James & Associates (0.03%), Fifth Third Bancorp (0.01%), Legacy Wealth Asset Management LLC (0.01%), Marotta Asset Management (0.00%), Park Avenue Securities LLC (0.00%) and Allspring Global Investments Holdings LLC (0.00%). How do I buy shares of Genmab A/S? Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GMAB) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 MediaThe Next Nvidia?InvestorPlaceExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersIs Tesla going out of business?DTI Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
